

# Recombinant Human EPO protein (His tag)

Catalog Number:PDEH100222



**Note:** Centrifuge before opening to ensure complete recovery of vial contents.

## Description

|                                    |                            |
|------------------------------------|----------------------------|
| <b>Synonyms</b>                    | Epoetin;EPO;Erythropoietin |
| <b>Species</b>                     | Human                      |
| <b>Expression Host</b>             | E.coli                     |
| <b>Sequence</b>                    | Ala 28-Arg 193             |
| <b>Accession</b>                   | P01588                     |
| <b>Calculated Molecular Weight</b> | 18.2 kDa                   |
| <b>Observed molecular weight</b>   | 20 kDa                     |
| <b>Tag</b>                         | C-His                      |

## Properties

|                       |   |
|-----------------------|---|
| <b>Purity</b>         | > 95 % as determined by reducing SDS-PAGE.  |
| <b>Endotoxin</b>      | Please contact us for more information.   |
| <b>Storage</b>        | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months. |
| <b>Shipping</b>       | This product is provided as lyophilized powder which is shipped with ice packs.   |
| <b>Formulation</b>    | Lyophilized from sterile PBS, pH 7.4.<br>Normally 5 % - 8 % trehalose, mannitol and 0.01 % Tween80 are added as protectants before lyophilization.<br>Please refer to the specific buffer information in the printed manual.          |
| <b>Reconstitution</b> | Please refer to the printed manual for detailed information.  |

## Background

Erythropoietin (EPO) is a 34 kDa glycoprotein hormone in the type I cytokine family and is related to thrombopoietin. Its three N-glycosylation sites, four alpha helices, and N- to C-terminal disulfide bond are conserved across species. Glycosylation of the EPO protein is required for biological activities in vivo. The mature human EPO protein shares 75% - 84% amino acid sequence identity with bovine, canine, equine, feline, mouse, ovine, porcine, and rat EPO. EPO is primarily produced in the kidney by a population of fibroblast-like cortical interstitial cells adjacent to the proximal tubules. It is also produced in much lower, but functionally significant amounts by fetal hepatocytes and in adult liver and brain. EPO promotes erythrocyte formation by preventing the apoptosis of early erythroid precursors which express the erythropoietin receptor (EPO R). EPO R has also been described in brain, retina, heart, skeletal muscle, kidney, endothelial cells, and a variety of tumor cells. Ligand induced dimerization of EPO R triggers JAK2-mediated signaling pathways followed by receptor/ligand endocytosis and degradation. Rapid regulation of circulating EPO allows tight control of erythrocyte production and hemoglobin concentrations. Anemia or other causes of low tissue oxygen tension induce erythropoietin production by stabilizing the hypoxia-inducible transcription factors HIF-1 alpha and HIF-2 alpha. EPO additionally plays a tissue-protective role in ischemia by blocking apoptosis and inducing angiogenesis.

## For Research Use Only

A Reliable Research Partner in Life Science and Medicine

Toll-free: 1-888-852-8623

Web: [www.elabscience.com](http://www.elabscience.com)

Tel: 1-832-243-6086

Email: [techsupport@elabscience.com](mailto:techsupport@elabscience.com)

Fax: 1-832-243-6017